|
| 36495784 | Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer. | Lung Cancer | 2023 |
| 36495784 | Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer. | Lung Cancer | 2023 |
| 36696540 | Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. | Blood Adv | 2023 |
| 36696540 | Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. | Blood Adv | 2023 |
| 34911336 | MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. | Future Oncol | 2022 |
| 36467814 | Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial. | EJHaem | 2022 |
| 34911336 | MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. | Future Oncol | 2022 |
| 36467814 | Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial. | EJHaem | 2022 |
| 33942292 | Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib. | Br J Haematol | 2021 |
| 33942292 | Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib. | Br J Haematol | 2021 |
| 34739844 | Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. | Cancer Cell | 2021 |
| 34739844 | Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. | Cancer Cell | 2021 |
| 30901302 | Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2019 |
| 30901302 | Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2019 |
| 29314097 | Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. | Prostate | 2018 |
| 29314097 | Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. | Prostate | 2018 |
| 26899759 | Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. | J Thorac Oncol | 2016 |
| 26899759 | Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. | J Thorac Oncol | 2016 |
| 25624436 | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. | J Clin Oncol | 2015 |
| 25624436 | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. | J Clin Oncol | 2015 |
| 26334219 | A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. | Invest New Drugs | 2015 |
| 26334219 | A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. | Invest New Drugs | 2015 |
| 25264305 | Crizotinib in ROS1-rearranged non-small-cell lung cancer. | N Engl J Med | 2014 |
| 25264305 | Crizotinib in ROS1-rearranged non-small-cell lung cancer. | N Engl J Med | 2014 |
| 22454420 | Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. | J Clin Oncol | 2012 |
| 22454420 | Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. | J Clin Oncol | 2012 |
| 20979469 | Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. | N Engl J Med | 2010 |
| 20979469 | Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. | N Engl J Med | 2010 |
| 19723875 | Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. | Mol Cancer Res | 2009 |
| 19723875 | Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. | Mol Cancer Res | 2009 |
| 18834404 | The role of metastasis suppressor genes in metastatic dormancy. | APMIS | 2008 |
| 18834404 | The role of metastasis suppressor genes in metastatic dormancy. | APMIS | 2008 |
| 10860852 | VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor. | Biochem Biophys Res Commun | 2000 |
| 10860852 | VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor. | Biochem Biophys Res Commun | 2000 |
| 9690816 | Heterogeneity of vascular endothelial cells in normal and disease states. | Pharmacol Ther | 1998 |
| 9690816 | Heterogeneity of vascular endothelial cells in normal and disease states. | Pharmacol Ther | 1998 |
| 9040693 | Human vascular endothelium heterogeneity. A comparative study of cerebral and peripheral cultured vascular endothelial cells. | Stroke | 1997 |
| 9336380 | Reversal of endothelin-1 release by stimulation of endothelial alpha2-adrenoceptor contributes to cerebral vasorelaxation. | Hypertension | 1997 |
| 9040693 | Human vascular endothelium heterogeneity. A comparative study of cerebral and peripheral cultured vascular endothelial cells. | Stroke | 1997 |
| 9336380 | Reversal of endothelin-1 release by stimulation of endothelial alpha2-adrenoceptor contributes to cerebral vasorelaxation. | Hypertension | 1997 |
| 8794903 | Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes. | Mol Pharmacol | 1996 |
| 8969783 | alpha-Thrombin upregulates G alpha i3 in human vascular endothelial cells. | Stroke | 1996 |
| 8993433 | Vasoactive intestinal peptide activates both Gs and Gi in lung. | Ann N Y Acad Sci | 1996 |
| 8794903 | Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes. | Mol Pharmacol | 1996 |
| 8969783 | alpha-Thrombin upregulates G alpha i3 in human vascular endothelial cells. | Stroke | 1996 |
| 8993433 | Vasoactive intestinal peptide activates both Gs and Gi in lung. | Ann N Y Acad Sci | 1996 |
| 7805763 | Identification of the alpha 1c-adrenoceptor in rabbit arteries and the human saphenous vein using the polymerase chain reaction. | Eur J Pharmacol | 1994 |
| 7805763 | Identification of the alpha 1c-adrenoceptor in rabbit arteries and the human saphenous vein using the polymerase chain reaction. | Eur J Pharmacol | 1994 |
| 1327840 | The alpha 1-adrenoceptor is inactivated by alterations in membrane phospholipids. | Eur J Pharmacol | 1992 |
| 1310685 | Evidence for the formation of a functional complex between vasoactive intestinal peptide, its receptor, and Gs in lung membranes. | J Biol Chem | 1992 |